Tumor-Derived Extracellular Mutations of PTPRT/PTPR Are Defective in Cell Adhesion

Total Page:16

File Type:pdf, Size:1020Kb

Tumor-Derived Extracellular Mutations of PTPRT/PTPR Are Defective in Cell Adhesion Tumor-Derived Extracellular Mutations of PTPRT/PTPR Are Defective in Cell Adhesion Jianshi Yu,1,2 Scott Becka,3 Peng Zhang,2 Xiaodong Zhang,1,2 Susann M. Brady-Kalnay,1,3,4 and Zhenghe Wang1,2,5 1Case Comprehensive Cancer Center and Departments of 2Genetics, 3Molecular Biology and Microbiology, and 4Neurosciences, School of Medicine, Case Western Reserve University; and 5Genomic Medicine Institute, Cleveland Clinic Foundation, Cleveland, Ohio Abstract nonsense mutations and frameshifts, suggested that these Receptor protein tyrosine phosphatase T (PTPRT/PTPR) mutations were inactivating (2). Biochemical analyses showed is frequently mutated in human cancers including colon, that missense mutations in the catalytic domains of PTPU lung, gastric, and skin cancers. More than half of the diminished its phosphatase activity, and overexpression of identified tumor-derived mutations are located in the PTPU inhibited colorectal cancer cell growth (2). Taken extracellular part of PTPR. However, the functional together, these studies strongly supported the notion that PTPU significance of those extracellular domain mutations normally acts as a tumor suppressor gene. This conclusion was remains to be defined. Here we report that the also supported by a transposon-based somatic mutagenesis extracellular domain of PTPR mediates homophilic screen in mice, in which PTPU was isolated as a target gene cell-cell aggregation. This homophilic interaction is very from two different mouse transgenic sarcomas (3). specific because PTPR does not interact with its closest PTPRT (PTPU) is a member of the type IIB receptor protein homologue, PTPM, in a cell aggregation assay. We tyrosine phosphatase (RPTP) subfamily (4). Other members of further showed that all five tumor-derived mutations this subfamily include PTPRM (PTPA), PTPRK (PTPn), and E k located in the NH2-terminal MAM and immunoglobulin PCP2 (also called PTP , PTPc, PTPRO-omicron, PTP ,or domains impair, to varying extents, their ability to form hPTP-J; ref. 5). These four RPTPs share the same domain cell aggregates, indicating that those mutations are structure: an extracelluar domain, a juxtamembrane region, and loss-of-function mutations. Our results suggest that two phosphatase domains (6). The extracellular domains of type PTPR may play an important role in cell-cell adhesion IIB RPTPs have high sequence identities (6-8), all consisting and that mutational inactivation of this phosphatase of a MAM (memprin/A5/PTPA) domain, an immunoglobulin could promote tumor migration and metastasis. domain, and four fibronectin type III repeats (6). The MAM (Mol Cancer Res 2008;6(7):1106–13) domain is suggested to play a role in protein dimerization (6). The immunoglobulin domain is a disulfide structure that is found in many cell surface proteins and has been shown to Introduction mediate homophilic and heterophilic interactions between cell Tyrosine phosphorylation is coordinately controlled by adhesion molecules (6). The fibronectin type III motif was protein tyrosine kinases and phosphatases and is a central originally identified in the extracellular matrix protein fibro- feature of many signaling pathways involved in tumor nectin and later found to be present in many immunoglobulin development (1). Whereas activating mutations in protein superfamily cell adhesion molecules (6). We have identified tyrosine kinases have been shown to play vital roles in f15 somatic mutations that are localized in the extracellular tumorigenesis (1), the role of phosphatases is less well defined. domain of PTPRT/PTPU. How these mutations affect the U We recently identified PTPRT, also known as PTP , as the most functions of PTPU remains to be determined. frequently mutated PTP gene in colorectal cancers (2). PTPRT Three close homologues of PTPU [PTPA, PTPn, and PTPE was also mutationally altered in lung cancer, gastric cancer, (PCP-2)] are known to mediate homophilic cell-cell adhesion and melanomas (2). The spectrum of mutations, which included (9-12). Expression of the full-length PTPA (9, 10) or a construct encoding the extracellular, transmembrane, and 55 amino acids of the juxtamembrane domain of PTPA in nonadhesive Sf9 insect cells induces cell aggregation (9). Furthermore, homo- Received 10/29/07; revised 2/29/08; accepted 4/9/08. A A Grant support: NIH grants R01-CA127590 and U54CA116867 (Z. Wang) and philic binding of PTP was shown between PTP -coated grants R01-EY12251 and RO1-NS051520 (S.M. Brady-Kalnay), the Concern fluorescent beads and cells that endogenously express PTPA Foundation, the V Foundation (Z. Wang), and Visual Sciences Research Center (9). The minimal region required for homophilic binding was Core Grant PO-EY11373 from the National Eye Institute (S.M. Brady-Kalnay). A The costs of publication of this article were defrayed in part by the payment of mapped to the immunoglobulin domain of PTP (13). In page charges. This article must therefore be hereby marked advertisement in addition, the immunoglobulin domain is required for proper cell accordance with 18 U.S.C. Section 1734 solely to indicate this fact. surface localization (14). However, assays that test cell-cell Requests for reprints: Zhenghe Wang, Department of Genetics and Case Comprehensive Cancer Center, Case Western Reserve University, Wolstein aggregation show that the MAM and immunoglobulin domains Research Building 3-120, 10900 Euclid Avenue, Cleveland, OH 44106. Phone: as well as the first two fibronectin type III repeats are required 216-368-0446; Fax: 216-368-8919. E-mail: [email protected] n Copyright D 2008 American Association for Cancer Research. for efficient cell-cell aggregation (15-18). Similarly, PTP was doi:10.1158/1541-7786.MCR-07-2123 also shown to mediate homophilic cell-cell aggregation (11). 1106 Mol Cancer Res 2008;6(7). July 2008 Downloaded from mcr.aacrjournals.org on September 30, 2021. © 2008 American Association for Cancer Research. PTPRT Mutations Are Defective in Cell Adhesion 1107 Here we report that PTPRT (PTPU), like its homologues, sion of single cells (Fig. 2). These results indicate that the mediates homophilic cell-cell aggregation in Sf9 cells. Most extracellular fragment of PTPU plays an important role in importantly, the tumor-derived mutations located in the MAM mediating cell-cell aggregation and that the phosphatase and immunoglobulin domains cause defective cell-cell adhesion activity of PTPU is not required for this function. Surprisingly, function. although the construct that encodes the PTPU extracellular fragment with the transmembrane domain sequences only Results (Extra-TM) was expressed on the cell surface (see Fig. 7), this The Extracellular Domain of PTPq Mediates Cell-Cell protein failed to mediate cell aggregation of Sf9 cells (Fig. 2), Aggregation in Sf9 Cells suggesting that additional juxtamembrane sequences are To test whether PTPU mediates homophilic cell-cell required for either forming or stabilizing the cell aggregates. adhesion, we made PTPU baculoviral constructs expressing (a) full-length PTPU;(b) the intracellular fragment of PTPU PTPq Mediates Highly Specific Homophilic Cell-Cell (Intra); (c) the extracellular fragment of PTPU with its Aggregation transmembrane domain (Extra-TM); (d) the extracellular To test whether PTPU mediates homophilic cell-cell fragment of PTPU with its transmembrane, juxtamembrane, aggregation, one set of Sf9 cells was infected with viruses and wedge domains (Extra-JMD-W); and (e)achimera expressing enhanced green fluorescent protein and another set containing the extracellular and transmembrane domains of of Sf9 cells was coinfected with viruses expressing the epidermal growth factor receptor and the intracellular PTP the full-length PTPU and red fluorescent protein. The green domains of PTPU (Fig. 1A). All of those fragments were tagged fluorescent protein–expressing cells were mixed with equal with V5 epitope tags. Proteins of the expected size were number of cells expressing full-length PTPU (coexpressing red expressed in Sf9 cells infected with those baculoviral constructs fluorescent protein) and the aggregation assays were done. (Fig. 1B). All of these proteins, but the intracellular PTPU, were As shown in Fig. 3A, the green fluorescent protein–labeled expressed on the surface on Sf9 cells (Figs. 1C and 7). To test cells did not aggregate and did not contribute to the aggregates whether these PTPU recombinant proteins mediate cell-cell formed by cells expressing full-length PTPU (red fluorescent adhesion, a cell aggregation assay was done following the protein). These results strongly suggest that the aggregation of procedure of Brady-Kalnay et al. (9). Sf9 cells infected with a Sf9 cells expressing PTPU is mediated through a homophilic baculovirus encoding PTPA, which was previously shown to interaction among PTPU molecules in trans, but not through a mediate cell-cell aggregation, were treated in parallel as a heterophilic interaction between molecules expressed on the positive control (Fig. 2). As shown in Fig. 2, the nonadhesive surface of Sf9 cells. Interestingly, the homophilic interaction Sf9 cells expressing either the full-length PTPU or PTPU-JMD- of PTPU is very specific. Although 63% of the amino acid W formed cell aggregates. On the contrary, Sf9 cells expressing sequences of the extracellular domain of PTPU are identical either the intracellular fragments of PTPU or the epidermal with that of PTPRM (PTPA), Sf9 cells expressing PTPU growth factor receptor/PTPU chimeras remained as a suspen- (coexpressing red fluorescent
Recommended publications
  • PTPRK Expression Is Downregulated in Drug Resistant Ovarian Cancer Cell Lines, and Especially in ALDH1A1 Positive Cscs-Like Popu
    Article PTPRK Expression Is Downregulated in Drug Resistant Ovarian Cancer Cell Lines, and Especially in ALDH1A1 Positive CSCs‐Like Populations Monika Świerczewska 1,*, Karolina Sterzyńska 1, Karolina Wojtowicz 1, Dominika Kaźmierczak 1, Dariusz Iżycki 2, Michał Nowicki 1, Maciej Zabel 1,3 and Radosław Januchowski 1 1 Department of Histology and Embryology, Poznan University of Medical Sciences, Święcickiego 6 St., 61‐781 Poznań, Poland; [email protected] (K.S.); [email protected] (K.W.); [email protected] (D.K.); [email protected] (M.N.); [email protected] (M.Z.); [email protected] (R.J.) 2 Department of Cancer Immunology, Poznan University of Medical Sciences, Garbary 15 St., 61‐866 Poznań, Poland; [email protected] 3 Department of Anatomy and Histology, University of Zielona Góra, Licealna 9 St., 65‐417 Zielona Góra, Poland * Correspondence: [email protected]; Tel.: +48‐61‐8546428 Received: 26 March 2019; Accepted: 24 April 2019; Published: 25 April 2019 Abstract: Background: Ovarian cancer is the 7th most common cancer and 8th most mortal cancer among woman. The standard treatment includes cytoreduction surgery followed by chemotherapy. Unfortunately, in most cases, after treatment, cancer develops drug resistance. Decreased expression and/or activity of protein phosphatases leads to increased signal transduction and development of drug resistance in cancer cells. Methods: Using sensitive (W1, A2780) and resistant ovarian cancer cell lines, the expression of Protein Tyrosine Phosphatase Receptor Type K (PTPRK) was performed at the mRNA (real‐time PCR analysis) and protein level (Western blot, immunofluorescence analysis). The protein expression in ovarian cancer tissues was determined by immunohistochemistry.
    [Show full text]
  • Single-Cell RNA Sequencing Demonstrates the Molecular and Cellular Reprogramming of Metastatic Lung Adenocarcinoma
    ARTICLE https://doi.org/10.1038/s41467-020-16164-1 OPEN Single-cell RNA sequencing demonstrates the molecular and cellular reprogramming of metastatic lung adenocarcinoma Nayoung Kim 1,2,3,13, Hong Kwan Kim4,13, Kyungjong Lee 5,13, Yourae Hong 1,6, Jong Ho Cho4, Jung Won Choi7, Jung-Il Lee7, Yeon-Lim Suh8,BoMiKu9, Hye Hyeon Eum 1,2,3, Soyean Choi 1, Yoon-La Choi6,10,11, Je-Gun Joung1, Woong-Yang Park 1,2,6, Hyun Ae Jung12, Jong-Mu Sun12, Se-Hoon Lee12, ✉ ✉ Jin Seok Ahn12, Keunchil Park12, Myung-Ju Ahn 12 & Hae-Ock Lee 1,2,3,6 1234567890():,; Advanced metastatic cancer poses utmost clinical challenges and may present molecular and cellular features distinct from an early-stage cancer. Herein, we present single-cell tran- scriptome profiling of metastatic lung adenocarcinoma, the most prevalent histological lung cancer type diagnosed at stage IV in over 40% of all cases. From 208,506 cells populating the normal tissues or early to metastatic stage cancer in 44 patients, we identify a cancer cell subtype deviating from the normal differentiation trajectory and dominating the metastatic stage. In all stages, the stromal and immune cell dynamics reveal ontological and functional changes that create a pro-tumoral and immunosuppressive microenvironment. Normal resident myeloid cell populations are gradually replaced with monocyte-derived macrophages and dendritic cells, along with T-cell exhaustion. This extensive single-cell analysis enhances our understanding of molecular and cellular dynamics in metastatic lung cancer and reveals potential diagnostic and therapeutic targets in cancer-microenvironment interactions. 1 Samsung Genome Institute, Samsung Medical Center, Seoul 06351, Korea.
    [Show full text]
  • CDH12 Cadherin 12, Type 2 N-Cadherin 2 RPL5 Ribosomal
    5 6 6 5 . 4 2 1 1 1 2 4 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 2 2 A A A A A A A A A A A A A A A A A A A A C C C C C C C C C C C C C C C C C C C C R R R R R R R R R R R R R R R R R R R R B , B B B B B B B B B B B B B B B B B B B , 9 , , , , 4 , , 3 0 , , , , , , , , 6 2 , , 5 , 0 8 6 4 , 7 5 7 0 2 8 9 1 3 3 3 1 1 7 5 0 4 1 4 0 7 1 0 2 0 6 7 8 0 2 5 7 8 0 3 8 5 4 9 0 1 0 8 8 3 5 6 7 4 7 9 5 2 1 1 8 2 2 1 7 9 6 2 1 7 1 1 0 4 5 3 5 8 9 1 0 0 4 2 5 0 8 1 4 1 6 9 0 0 6 3 6 9 1 0 9 0 3 8 1 3 5 6 3 6 0 4 2 6 1 0 1 2 1 9 9 7 9 5 7 1 5 8 9 8 8 2 1 9 9 1 1 1 9 6 9 8 9 7 8 4 5 8 8 6 4 8 1 1 2 8 6 2 7 9 8 3 5 4 3 2 1 7 9 5 3 1 3 2 1 2 9 5 1 1 1 1 1 1 5 9 5 3 2 6 3 4 1 3 1 1 4 1 4 1 7 1 3 4 3 2 7 6 4 2 7 2 1 2 1 5 1 6 3 5 6 1 3 6 4 7 1 6 5 1 1 4 1 6 1 7 6 4 7 e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p m m m m m m m m m m m m m m m m m m m m m m m m m m m m m m m m m m m m m m m m m m m m m m m m m m m m
    [Show full text]
  • The Regulatory Roles of Phosphatases in Cancer
    Oncogene (2014) 33, 939–953 & 2014 Macmillan Publishers Limited All rights reserved 0950-9232/14 www.nature.com/onc REVIEW The regulatory roles of phosphatases in cancer J Stebbing1, LC Lit1, H Zhang, RS Darrington, O Melaiu, B Rudraraju and G Giamas The relevance of potentially reversible post-translational modifications required for controlling cellular processes in cancer is one of the most thriving arenas of cellular and molecular biology. Any alteration in the balanced equilibrium between kinases and phosphatases may result in development and progression of various diseases, including different types of cancer, though phosphatases are relatively under-studied. Loss of phosphatases such as PTEN (phosphatase and tensin homologue deleted on chromosome 10), a known tumour suppressor, across tumour types lends credence to the development of phosphatidylinositol 3--kinase inhibitors alongside the use of phosphatase expression as a biomarker, though phase 3 trial data are lacking. In this review, we give an updated report on phosphatase dysregulation linked to organ-specific malignancies. Oncogene (2014) 33, 939–953; doi:10.1038/onc.2013.80; published online 18 March 2013 Keywords: cancer; phosphatases; solid tumours GASTROINTESTINAL MALIGNANCIES abs in sera were significantly associated with poor survival in Oesophageal cancer advanced ESCC, suggesting that they may have a clinical utility in Loss of PTEN (phosphatase and tensin homologue deleted on ESCC screening and diagnosis.5 chromosome 10) expression in oesophageal cancer is frequent, Cao et al.6 investigated the role of protein tyrosine phosphatase, among other gene alterations characterizing this disease. Zhou non-receptor type 12 (PTPN12) in ESCC and showed that PTPN12 et al.1 found that overexpression of PTEN suppresses growth and protein expression is higher in normal para-cancerous tissues than induces apoptosis in oesophageal cancer cell lines, through in 20 ESCC tissues.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2003/0082511 A1 Brown Et Al
    US 20030082511A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2003/0082511 A1 Brown et al. (43) Pub. Date: May 1, 2003 (54) IDENTIFICATION OF MODULATORY Publication Classification MOLECULES USING INDUCIBLE PROMOTERS (51) Int. Cl." ............................... C12O 1/00; C12O 1/68 (52) U.S. Cl. ..................................................... 435/4; 435/6 (76) Inventors: Steven J. Brown, San Diego, CA (US); Damien J. Dunnington, San Diego, CA (US); Imran Clark, San Diego, CA (57) ABSTRACT (US) Correspondence Address: Methods for identifying an ion channel modulator, a target David B. Waller & Associates membrane receptor modulator molecule, and other modula 5677 Oberlin Drive tory molecules are disclosed, as well as cells and vectors for Suit 214 use in those methods. A polynucleotide encoding target is San Diego, CA 92121 (US) provided in a cell under control of an inducible promoter, and candidate modulatory molecules are contacted with the (21) Appl. No.: 09/965,201 cell after induction of the promoter to ascertain whether a change in a measurable physiological parameter occurs as a (22) Filed: Sep. 25, 2001 result of the candidate modulatory molecule. Patent Application Publication May 1, 2003 Sheet 1 of 8 US 2003/0082511 A1 KCNC1 cDNA F.G. 1 Patent Application Publication May 1, 2003 Sheet 2 of 8 US 2003/0082511 A1 49 - -9 G C EH H EH N t R M h so as se W M M MP N FIG.2 Patent Application Publication May 1, 2003 Sheet 3 of 8 US 2003/0082511 A1 FG. 3 Patent Application Publication May 1, 2003 Sheet 4 of 8 US 2003/0082511 A1 KCNC1 ITREXCHO KC 150 mM KC 2000000 so 100 mM induced Uninduced Steady state O 100 200 300 400 500 600 700 Time (seconds) FIG.
    [Show full text]
  • Targeting Protein Tyrosine Phosphatases in Cancer Lakshmi Reddy Bollu, Abhijit Mazumdar, Michelle I
    Published OnlineFirst January 13, 2017; DOI: 10.1158/1078-0432.CCR-16-0934 Molecular Pathways Clinical Cancer Research Molecular Pathways: Targeting Protein Tyrosine Phosphatases in Cancer Lakshmi Reddy Bollu, Abhijit Mazumdar, Michelle I. Savage, and Powel H. Brown Abstract The aberrant activation of oncogenic signaling pathways is a act as tumor suppressor genes by terminating signal responses universal phenomenon in cancer and drives tumorigenesis and through the dephosphorylation of oncogenic kinases. More malignant transformation. This abnormal activation of signal- recently, it has become clear that several PTPs overexpressed ing pathways in cancer is due to the altered expression of in human cancers do not suppress tumor growth; instead, they protein kinases and phosphatases. In response to extracellular positively regulate signaling pathways and promote tumor signals, protein kinases activate downstream signaling path- development and progression. In this review, we discuss both ways through a series of protein phosphorylation events, ulti- types of PTPs: those that have tumor suppressor activities as mately producing a signal response. Protein tyrosine phospha- well as those that act as oncogenes. We also discuss the tases (PTP) are a family of enzymes that hydrolytically remove potential of PTP inhibitors for cancer therapy. Clin Cancer Res; phosphate groups from proteins. Initially, PTPs were shown to 23(9); 1–7. Ó2017 AACR. Background in cancer and discuss the current status of PTP inhibitors for cancer therapy. Signal transduction is a complex process that transmits extra- PTPs belong to a superfamily of enzymes that hydrolytically cellular signals effectively through a cascade of events involving remove phosphate groups from proteins (2).
    [Show full text]
  • The PTPRT Pseudo-Phosphatase Domain Is a Denitrase
    bioRxiv preprint doi: https://doi.org/10.1101/238980; this version posted December 22, 2017. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. The PTPRT pseudo-phosphatase domain is a denitrase Yiqing Zhao1,2,#, Shuliang Zhao3,1,#, Yujun Hao1,2, Benlian Wang4, Peng Zhang1,2, Xiujing Feng1,2, Yicheng Chen1,2, Jing Song4, John Mieyal5, Sanford Markowitz1,2,6,7, Rob M. Ewing8,4, Ronald A. Conlon1,2, Masaru Miyagi4 and Zhenghe Wang1,2* 1Department of Genetics and Genome Sciences, 2Case Comprehensive Cancer Center, 4Department of Nutrition and Center for Proteomics and Bioinformatics, 5Department of Pharmacology, 6Department of Medicine, Case Western Reserve University, 10900 Euclid Avenue, Cleveland, Ohio 44106. 3Division of Gastroenterology and Hepatology and Shanghai Institution of Digestive Disease; Shanghai Jiao-Tong University School of Medicine Renji Hospital, 145 Middle Shandong Rd, Shanghai 200001, China. 7Seidman Cancer Center, University Hospitals Cleveland Medical Center, Cleveland, OH 44106. 8Computational and Systems Biology, School of Biological Sciences, University of Southampton, Southampton SO171BJ, UK * To whom correspondence should be addressed. Email: [email protected] # These authors contributed equally. bioRxiv preprint doi: https://doi.org/10.1101/238980; this version posted December 22, 2017. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. Abstract Protein tyrosine nitration occurs under both physiological and pathological conditions1. However, enzymes that remove this protein modification have not yet been identified. Here we report that the pseudo-phosphatase domain of protein tyrosine receptor T (PTPRT) is a denitrase that removes nitro-groups from tyrosine residues in paxillin.
    [Show full text]
  • Genetic Alterations of Protein Tyrosine Phosphatases in Human Cancers
    Oncogene (2015) 34, 3885–3894 © 2015 Macmillan Publishers Limited All rights reserved 0950-9232/15 www.nature.com/onc REVIEW Genetic alterations of protein tyrosine phosphatases in human cancers S Zhao1,2,3, D Sedwick3,4 and Z Wang2,3 Protein tyrosine phosphatases (PTPs) are enzymes that remove phosphate from tyrosine residues in proteins. Recent whole-exome sequencing of human cancer genomes reveals that many PTPs are frequently mutated in a variety of cancers. Among these mutated PTPs, PTP receptor T (PTPRT) appears to be the most frequently mutated PTP in human cancers. Beside PTPN11, which functions as an oncogene in leukemia, genetic and functional studies indicate that most of mutant PTPs are tumor suppressor genes. Identification of the substrates and corresponding kinases of the mutant PTPs may provide novel therapeutic targets for cancers harboring these mutant PTPs. Oncogene (2015) 34, 3885–3894; doi:10.1038/onc.2014.326; published online 29 September 2014 INTRODUCTION tyrosine/threonine-specific phosphatases. (4) Class IV PTPs include Protein tyrosine phosphorylation has a critical role in virtually all four Drosophila Eya homologs (Eya1, Eya2, Eya3 and Eya4), which human cellular processes that are involved in oncogenesis.1 can dephosphorylate both tyrosine and serine residues. Protein tyrosine phosphorylation is coordinately regulated by protein tyrosine kinases (PTKs) and protein tyrosine phosphatases 1 THE THREE-DIMENSIONAL STRUCTURE AND CATALYTIC (PTPs). Although PTKs add phosphate to tyrosine residues in MECHANISM OF PTPS proteins, PTPs remove it. Many PTKs are well-documented oncogenes.1 Recent cancer genomic studies provided compelling The three-dimensional structures of the catalytic domains of evidence that many PTPs function as tumor suppressor genes, classical PTPs (RPTPs and non-RPTPs) are extremely well because a majority of PTP mutations that have been identified in conserved.5 Even the catalytic domain structures of the dual- human cancers are loss-of-function mutations.
    [Show full text]
  • Comprehensive Protein Tyrosine Phosphatase Mrna Profiling Identifies New Regulators in the Progression of Glioma Annika M
    Bourgonje et al. Acta Neuropathologica Communications (2016) 4:96 DOI 10.1186/s40478-016-0372-x RESEARCH Open Access Comprehensive protein tyrosine phosphatase mRNA profiling identifies new regulators in the progression of glioma Annika M. Bourgonje1, Kiek Verrijp2, Jan T. G. Schepens1, Anna C. Navis2, Jolanda A. F. Piepers1, Chantal B. C. Palmen1, Monique van den Eijnden4, Rob Hooft van Huijsduijnen4, Pieter Wesseling2,3, William P. J. Leenders2 and Wiljan J. A. J. Hendriks1* Abstract The infiltrative behavior of diffuse gliomas severely reduces therapeutic potential of surgical resection and radiotherapy, and urges for the identification of new drug-targets affecting glioma growth and migration. To address the potential role of protein tyrosine phosphatases (PTPs), we performed mRNA expression profiling for 91 of the 109 known human PTP genes on a series of clinical diffuse glioma samples of different grades and compared our findings with in silico knowledge from REMBRANDT and TCGA databases. Overall PTP family expression levels appeared independent of characteristic genetic aberrations associated with lower grade or high grade gliomas. Notably, seven PTP genes (DUSP26, MTMR4, PTEN, PTPRM, PTPRN2, PTPRT and PTPRZ1) were differentially expressed between grade II-III gliomas and (grade IV) glioblastomas. For DUSP26, PTEN, PTPRM and PTPRT, lower expression levels correlated with poor prognosis, and overexpression of DUSP26 or PTPRT in E98 glioblastoma cells reduced tumorigenicity. Our study represents the first in-depth analysis of PTP family expression in diffuse glioma subtypes and warrants further investigations into PTP-dependent signaling events as new entry points for improved therapy. Keywords: Glioblastoma, Astrocytoma, EGFR, Oligodendroglioma, IDH1, DUSP26, MTMR4, PTEN, PTP, PTPRM, PTPRN2, PTPRT, PTPRZ1, Malignancy Introduction has slightly improved over the past decades, the prospect Gliomas arise from glial (precursor) cells and represent with current treatment is only a median 15 months fol- the most frequent type of primary brain tumor.
    [Show full text]
  • Protein Tyrosine Phosphatase PTPN3 Inhibits Lung Cancer Cell Proliferation and Migration by Promoting EGFR Endocytic Degradation
    Oncogene (2015) 34, 3791–3803 © 2015 Macmillan Publishers Limited All rights reserved 0950-9232/15 www.nature.com/onc ORIGINAL ARTICLE Protein tyrosine phosphatase PTPN3 inhibits lung cancer cell proliferation and migration by promoting EGFR endocytic degradation M-Y Li1,2, P-L Lai1, Y-T Chou3, A-P Chi1, Y-Z Mi1, K-H Khoo1,2, G-D Chang2, C-W Wu3, T-C Meng1,2 and G-C Chen1,2 Epidermal growth factor receptor (EGFR) regulates multiple signaling cascades essential for cell proliferation, growth and differentiation. Using a genetic approach, we found that Drosophila FERM and PDZ domain-containing protein tyrosine phosphatase, dPtpmeg, negatively regulates border cell migration and inhibits the EGFR/Ras/mitogen-activated protein kinase signaling pathway during wing morphogenesis. We further identified EGFR pathway substrate 15 (Eps15) as a target of dPtpmeg and its human homolog PTPN3. Eps15 is a scaffolding adaptor protein known to be involved in EGFR endocytosis and trafficking. Interestingly, PTPN3-mediated tyrosine dephosphorylation of Eps15 promotes EGFR for lipid raft-mediated endocytosis and lysosomal degradation. PTPN3 and the Eps15 tyrosine phosphorylation-deficient mutant suppress non-small-cell lung cancer cell growth and migration in vitro and reduce lung tumor xenograft growth in vivo. Moreover, depletion of PTPN3 impairs the degradation of EGFR and enhances proliferation and tumorigenicity of lung cancer cells. Taken together, these results indicate that PTPN3 may act as a tumor suppressor in lung cancer through its modulation of EGFR signaling. Oncogene (2015) 34, 3791–3803; doi:10.1038/onc.2014.312; published online 29 September 2014 INTRODUCTION sorting EGFR to multivesicular bodies.15 Recently, Ali et al.16 Reversible tyrosine protein phosphorylation by protein tyrosine showed that the ESCRT accessory protein HD-PTP/PTPN23 kinases and protein tyrosine phosphatases (PTPs) acts as a coordinates with the ubiquitin-specific peptidase UBPY to drive molecular switch that regulates a variety of biological pro- EGFR sorting to the multivesicular bodies.
    [Show full text]
  • RT² Profiler PCR Array (96-Well Format and 384-Well [4 X 96] Format)
    RT² Profiler PCR Array (96-Well Format and 384-Well [4 x 96] Format) Human Protein Phosphatases Cat. no. 330231 PAHS-045ZA For pathway expression analysis Format For use with the following real-time cyclers RT² Profiler PCR Array, Applied Biosystems® models 5700, 7000, 7300, 7500, Format A 7700, 7900HT, ViiA™ 7 (96-well block); Bio-Rad® models iCycler®, iQ™5, MyiQ™, MyiQ2; Bio-Rad/MJ Research Chromo4™; Eppendorf® Mastercycler® ep realplex models 2, 2s, 4, 4s; Stratagene® models Mx3005P®, Mx3000P®; Takara TP-800 RT² Profiler PCR Array, Applied Biosystems models 7500 (Fast block), 7900HT (Fast Format C block), StepOnePlus™, ViiA 7 (Fast block) RT² Profiler PCR Array, Bio-Rad CFX96™; Bio-Rad/MJ Research models DNA Format D Engine Opticon®, DNA Engine Opticon 2; Stratagene Mx4000® RT² Profiler PCR Array, Applied Biosystems models 7900HT (384-well block), ViiA 7 Format E (384-well block); Bio-Rad CFX384™ RT² Profiler PCR Array, Roche® LightCycler® 480 (96-well block) Format F RT² Profiler PCR Array, Roche LightCycler 480 (384-well block) Format G RT² Profiler PCR Array, Fluidigm® BioMark™ Format H Sample & Assay Technologies Description The Human Protein Phosphatases RT² Profiler PCR Array profiles the gene expression of the 84 most important and well-studied phosphatases in the mammalian genome. By reversing the phosphorylation of key regulatory proteins mediated by protein kinases, phosphatases serve as a very important complement to kinases and attenuate activated signal transduction pathways. The gene classes on this array include both receptor and non-receptor tyrosine phosphatases, catalytic subunits of the three major protein phosphatase gene families, the dual specificity phosphatases, as well as cell cycle regulatory and other protein phosphatases.
    [Show full text]
  • Supplementary Table 1
    Supplementary Table 1. 492 genes are unique to 0 h post-heat timepoint. The name, p-value, fold change, location and family of each gene are indicated. Genes were filtered for an absolute value log2 ration 1.5 and a significance value of p ≤ 0.05. Symbol p-value Log Gene Name Location Family Ratio ABCA13 1.87E-02 3.292 ATP-binding cassette, sub-family unknown transporter A (ABC1), member 13 ABCB1 1.93E-02 −1.819 ATP-binding cassette, sub-family Plasma transporter B (MDR/TAP), member 1 Membrane ABCC3 2.83E-02 2.016 ATP-binding cassette, sub-family Plasma transporter C (CFTR/MRP), member 3 Membrane ABHD6 7.79E-03 −2.717 abhydrolase domain containing 6 Cytoplasm enzyme ACAT1 4.10E-02 3.009 acetyl-CoA acetyltransferase 1 Cytoplasm enzyme ACBD4 2.66E-03 1.722 acyl-CoA binding domain unknown other containing 4 ACSL5 1.86E-02 −2.876 acyl-CoA synthetase long-chain Cytoplasm enzyme family member 5 ADAM23 3.33E-02 −3.008 ADAM metallopeptidase domain Plasma peptidase 23 Membrane ADAM29 5.58E-03 3.463 ADAM metallopeptidase domain Plasma peptidase 29 Membrane ADAMTS17 2.67E-04 3.051 ADAM metallopeptidase with Extracellular other thrombospondin type 1 motif, 17 Space ADCYAP1R1 1.20E-02 1.848 adenylate cyclase activating Plasma G-protein polypeptide 1 (pituitary) receptor Membrane coupled type I receptor ADH6 (includes 4.02E-02 −1.845 alcohol dehydrogenase 6 (class Cytoplasm enzyme EG:130) V) AHSA2 1.54E-04 −1.6 AHA1, activator of heat shock unknown other 90kDa protein ATPase homolog 2 (yeast) AK5 3.32E-02 1.658 adenylate kinase 5 Cytoplasm kinase AK7
    [Show full text]